Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits i...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose, Anna Nikonova, Michel Pavic, April Shamy, Jean Roy, Michael Sebag, Sabrina Trudel, Jean-Sébastien Claveau
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Current Oncology
Subjects:
bispecific antibodies
multiple myeloma
targeted immunotherapy
toxicity
Online Access:https://www.mdpi.com/1718-7729/32/4/238
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/4/238

Similar Items